Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance
British Journal of Cancer - United Kingdom
doi 10.1038/s41416-019-0428-3
Full Text
Open PDFAbstract
Available in full text
Date
March 18, 2019
Authors
Publisher
Springer Science and Business Media LLC